Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “therapy”

782 pharma patents match "therapy" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 782
Index total 30,257
Page 16 / 33

Quick answer

This filtered view shows 782 pharmaceutical patents matching "therapy" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

782 results for “therapy” · 30,257 patents in full index Clear search

  1. US 10675482

    Device and method for use of photodynamic therapy

    Craniovation, Inc. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  2. US 10661095

    Photodynamic therapy for use in treating cancer

    The Board of Regents of the University of Texas System · Granted May 26, 2020 · Expires May 21, 2040

    granted
  3. US 10653789

    Polymer-drug conjugates for combination anticancer therapy

    The Regents of the University of California · Granted May 19, 2020 · Expires May 14, 2040

    granted
  4. US 10653723

    Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted May 19, 2020 · Expires May 14, 2040

    granted
  5. US 10653710

    Combination therapy for treating malignancies

    Agios Pharmaceuticals, Inc. · Granted May 19, 2020 · Expires May 14, 2040

    granted
  6. US 10646517

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted May 12, 2020 · Expires May 7, 2040

    granted
  7. US 10639330

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  8. US 10632114

    Pyruvate kinase activators for use in therapy

    Agios Pharmaceuticals, Inc. · Granted Apr 28, 2020 · Expires Apr 23, 2040

    granted
  9. US 10618967

    Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Apr 14, 2020 · Expires Apr 9, 2040

    granted
  10. US 10610535

    Diarylpropionitrile therapy for treatment of multiple sclerosis

    The Regents of the University of California · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  11. US 10576096

    Tumor-selective combination therapy

    The Board of Regents of the University of Texas System · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  12. US 10568873

    Safranal-sorafenib combination therapy for liver cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted
  13. US 10568963

    Multifunctional nanoplatforms for fluorescence imaging and photodynamic therapy developed by post-loading photosensitizer and fluorophore to polyacrylamide nanoparticles

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted
  14. US 10544223

    Combination therapy with an anti-axl antibody-drug conjugate

    ADC THERAPEUTICS SA · Granted Jan 28, 2020 · Expires Jan 23, 2040

    granted
  15. US 10543222

    Therapy for inhibition of single-stranded RNA virus replication

    RedHill Biopharma Ltd. · Granted Jan 28, 2020 · Expires Jan 23, 2040

    granted
  16. US 10537595

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  17. US 10537635

    Detection of arginine methylation of EGFR for prediction of resistance to therapy

    The Board of Regents of the University of Texas System · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  18. US 10533227

    Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer

    The Board of Regents of the University of Texas System · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  19. US 10525104

    Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  20. US 10526414

    Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases

    VACCINEX, INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  21. US 10517948

    Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy

    The Board of Regents of the University of Texas System · Granted Dec 31, 2019 · Expires Dec 26, 2039

    granted
  22. US 10493162

    Somatostatin receptor-based cancer therapy

    The Board of Regents of the University of Texas System · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted
  23. US 10485886

    Core-satellite nanocomposites for MRI and photothermal therapy

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 26, 2019 · Expires Nov 21, 2039

    granted
  24. US 10488416

    Targeting breast cancer therapy based on stromal subtypes and CD146 composition

    The Regents of the University of Colorado, a Body Corporate · Granted Nov 26, 2019 · Expires Nov 21, 2039

    granted